|View printer-friendly version|
"This is a groundbreaking study -- the first to report on the efficacy and toxicity of SBRT in the treatment of low-risk prostate cancer following 10 years of treatment. All patients participating in the study were treated with the CyberKnife System, which delivers extremely precise radiation treatments using unique, real-time image guidance and automatic motion correction. The study outcomes were excellent both in terms of disease control and tolerability, and were superior to long-term conventional intensity-modulated radiation therapy, based on results from other studies," said
CyberKnife SBRT provides significant treatment benefits
Study participants completed their entire treatment in just five daily sessions, compared to conventional radiation therapy which typically takes 30 to 40 sessions. Additional 10-year outcomes showed:
The prostate gland can move unpredictably throughout the course of treatment, making the ability to track, detect and correct for motion critically important. Throughout the course of treatment, the CyberKnife System continually collects images to determine exactly where the tumor is, ensuring that clinicians deliver radiation exactly where they want it. The System detects the tumor motion and automatically adjusts the radiation beam in real time to match the motion of the tumor, giving clinicians confidence to apply smaller treatment margins and enabling higher doses and fewer treatments.
"Following early stage prostate cancer diagnosis men have a variety of treatment options from which to choose. CyberKnife prostate SBRT is increasingly being selected by men with low- or intermediate-risk disease who opt for treatment with radiation therapy," said Fabienne Hirigoyenberry-Lanson, VP Global Medical and Scientific Affairs of
About the Study
In this study, 230 low-risk prostate cancer patients received a CyberKnife® treatment dose of 35 Gray (Gy) or 36.25 Gy on five consecutive days. All patients had a Gleason score of six and a
Important Safety Information
For Important Safety Information please refer to http://www.accuray.com/safety-statement
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient experiences and outcomes, and
Forward-looking statements speak only as of the date the statements are made and are based on information available to
Public Relations Director,
+1 (408) 789-4426
+1 (781) 684-0770
© 2007 - 2016 Accuray Incorporated. All Rights Reserved. Accuray, the stylized logo, CyberKnife, TomoTherapy, Synchrony, Xsight, Xchange, TomoHD, Hi-Art, and RoboCouch are among the trademarks and / or registered trademarks of Accuray Incorporated in the United States and other countries.
Important Safety Information: Most side effects of radiotherapy, including radiotherapy delivered with Accuray systems, are mild and temporary, often involving fatigue, nausea, and skin irritation. Side effects can be severe, however, leading to pain, alterations in normal body functions (for example, urinary or salivary function), deterioration of quality of life, permanent injury and even death.
Side effects can occur during or shortly after radiation treatment or in the months and years following radiation. The nature and severity of side effects depend on many factors, including the size and location of the treated tumor, the treatment technique (for example, the radiation dose), the patient's general medical condition, to name a few. For more details about the side effects of your radiation therapy, and if treatment with an Accuray product is right for you, ask your doctor.